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ABSTRACT
To gain insight into miRNA regulation in metastasis formation, we used a 
metastasis cell line model that allows investigation of extravasation and colonization 
of circulating cancer cells to lungs in mice. Using global miRNA profiling, 28 miRNAs 
were found to exhibit significantly altered expression between isogenic metastasizing 
and non-metastasizing cancer cells, with miR-155 being the most differentially 
expressed. Highly metastatic mesenchymal-like CL16 cancer cells showed very low 
miR-155 expression, and miR-155 overexpression in these cells lead to significantly 
decreased tumor burden in lungs when injected intravenously in immunodeficient 
mice. Our experiments addressing the underlying mechanism of the altered tumor 
burden revealed that miR-155-overexpressing CL16 cells were less invasive than 
CL16 control cells in vitro, while miR-155 overexpression had no effect on cancer cell 
proliferation or apoptosis in established lung tumors. To identify proteins regulated 
by miR-155 and thus delineate its function in our cell model, we compared the 
proteome of xenograft tumors derived from miR-155-overexpressing CL16 cells and 
CL16 control cells using mass spectrometry-based proteomics. >4,000 proteins were 
identified, of which 92 were consistently differentially expressed. Network analysis 
revealed that the altered proteins were associated with cellular functions such as 
movement, growth and survival as well as cell-to-cell signaling and interaction. 
Downregulation of the three metastasis-associated proteins ALDH1A1, PIR and PDCD4 
in miR-155-overexpressing tumors was validated by immunohistochemistry. Our 
results demonstrate that miR-155 inhibits the ability of cancer cells to extravasate 
and/or colonize at distant organs and brings additional insight into the complexity 
of miR-155 regulation in metastatic seeding.
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INTRODUCTION
Metastasis is the primary cause of cancer-related 
deaths and remains the most significant challenge to 
disease management. Establishment of metastases at 
distant sites results from a complex cascade of events 
that have not yet been fully elucidated. The process 
involves escape of malignant cells from the primary 
tumor, intravasation and subsequent spread through the 
circulatory system (lymph or blood) to distant locations 
where they extravasate, colonize, induce angiogenesis 
and undergo expansive growth [1, 2]. While some of these 
disseminated cancer cells have the molecular capacity 
to colonize and establish metastasis, others remain 
dormant in the new microenvironment within distant 
organs. Recently, microRNAs (miRNAs), a class of small 
regulatory RNAs, have been implicated in metastasis 
development [3].
miRNAs are approximately 22 nucleotide-long, 
non-coding RNA molecules that regulate many different 
biological functions in normal cells, including growth, 
differentiation and apoptosis by binding to mRNA and 
inducing translational repression or cleavage of the 
mRNA target. miRNAs have been shown to be involved 
in both initiation and progression of cancer [4, 5]. A single 
miRNA can regulate multiple mRNA targets, and a single 
mRNA may be regulated by multiple miRNAs, therefore 
the specific function of a single miRNA can be difficult to 
elucidate.
In relation to cancer, miR-155 is a miRNA 
predominantly known as an oncomir that is upregulated 
in several cancers, including B cell lymphomas, breast, 
lung and colon cancers [6–10]. In addition to its 
oncogenic function, high miR-155 expression is also 
associated with lymph node metastasis and poor overall 
survival [8, 11, 12]. Although miR-155 is predominately 
known as an oncogene, it has also been found to be 
downregulated in human melanoma cell lines compared 
to healthy melanocytes, and re-expression of miR-155 
led to inhibition of proliferation and induced apoptosis, 
suggesting a tumor suppressor role [13]. Interestingly, 
in triple-negative breast cancer, studies have shown that 
high miR-155 levels in the primary breast tumor correlate 
with better patient outcome, and that miR-155 inhibits 
metastasis development [14, 15]. These differing results 
highlight the need for further investigation into the role 
of miR-155.
Analysis of the individual steps of the complex 
metastatic process cannot be accomplished using patient 
tissue or in vitro assays, but in vivo mouse models based 
on inoculation of isogenic human cell lines with different 
phenotypes may allow studies of these processes as well 
as provide the means for comparative molecular screening 
and functional evaluation of candidate metastasis-related 
genes and proteins. One such metastasis model is based 
on the isogenic cell lines, NM-2C5 and M-4A4, which are 
equally tumorigenic in immunodeficient mice, but only the 
latter produces metastases in the lungs and lymph nodes. 
Although NM-2C5-derived primary tumors disseminate 
single cells to the lungs, they remain dormant and do 
not form metastases [16, 17]. Two additional cell lines, 
M-4A4-LM3–2 GFP (LM3) and M-4A4-LM3–4 CL-16 
GFP (CL16), derived from M-4A4 by serial passage in 
mice, exhibit incrementally increased metastatic potential 
when inoculated into mice [18–20]. Hence, the model 
recapitulates the mechanistic steps of extravasation and 
colonization of circulating cancer cell at distant sites, 
while avoiding the inherent problems of variations 
in the genetic backgrounds of human tissue samples. 
Additionally, this model overcomes the complexities of 
identifying cells with metastatic potential from primary 
tumors [16, 17]. Protein and gene expression of NM-2C5 
and M-4A4 cells have been extensively studied [21–28]. 
In addition, proteomic comparison of CL16 and M-4A4 
has showed that the expression of only a few proteins 
differed between the two cell lines [26].
We describe herein a panel of 28 miRNAs that 
exhibited significantly altered expression in these 
metastatic versus non-metastatic cell lines. miR-155 
exhibited the greatest alteration in expression, and further 
investigation of its function in these cancer cells showed 
that miR-155, when overexpressed in mesenchymal-like 
CL16 cells, inhibited their ability to extravasate, colonize 
and form tumors in lungs when injected into the tail vein of 
mice. Further, proteins exhibiting altered expression upon 
miR-155 upregulation were examined by comparative mass 
spectrometry-based proteomic analysis of xenograft tumors 
derived from CL16 cells overexpressing miR-155 vs. those 
derived from CL16 control cells. These results indicate 
miR-155 involvement in metastatic seeding and secondary 
tumor outgrowth in mesenchymal-like cancer cells.
RESULTS
miRNA expression profiling identified altered 
expression of miR-155 in metastatic vs. 
non-metastatic isogenic cancer cell lines
Identification of miRNAs potentially associated 
with the ability of tumor cells to extravasate, colonize 
and metastasize to distant organs was accomplished by 
miRNA expression profiling of a metastasis model. Two 
biological replicates of the isogenic metastatic cancer 
cell lines, M-4A4 and LM3, and the non-metastatic 
cancer cell line NM-2C5, were compared using LNA-
based microRNA microarray analysis. Each biological 
replicate was analyzed on two separate arrays. Raw data 
was deposited in the Gene Expression Omnibus (GEO) 
database (GSE37719). An unsupervised hierarchical 
clustering based on the 15 miRNAs that varied the most 
between samples (SD > 0.5) distinguished metastatic from 
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non-metastatic cell lines (Suppl Fig. 1), indicating that the 
largest difference between all samples was their metastatic 
capability. Subsequently, a Student’s t-test revealed 28 
mature human miRNAs that exhibited significantly altered 
expression between the metastatic and non-metastatic cell 
line groups (Var > 0.3, p < 0.01 (FDR = 0.06)) (Table 1). 
Hierarchical clustering based on these 28 miRNAs clearly 
distinguished the metastatic from non-metastatic cell 
Table 1: Twenty-eight mature miRNAs and one small nucleolar (SNORD) RNA exhibiting 
significantly altered expressed in isogenic non-metastatic vs. metastatic cell lines
miRNA ID p-Value FDR Fold change
hsa-miR-155 4.2E-07 5.69E-05 3.14
hsa-miR-130a 6.4E-07 5.69E-05 1.92
hsa-miR-363 1.1E-04 3.31E-03 1.66
hsa-miR-138 1.1E-03 1.24E-02 1.64
hsa-miR-801 3.7E-04 8.23E-03 1.61
hsa-miR-99a 1.8E-05 1.10E-03 1.58
hsa-miR-222 1.7E-03 1.75E-02 1.57
hsa-miR-20b 1.0E-03 1.24E-02 1.52
hsa-miR-455–3p 2.7E-04 6.86E-03 1.51
hsa-miR-221 7.7E-05 2.77E-03 1.51
hsa-miR-23a 4.1E-04 8.24E-03 1.46
hsa-miR-20a 9.2E-04 1.24E-02 1.45
hsa-miR-106a-5p 2.9E-03 2.60E-02 1.44
454_hsa_miR_2394 7.9E-04 1.24E-02 1.44
hsa-miR-17 3.4E-03 2.77E-02 1.43
hsa-miR-106a-3p 1.8E-03 1.75E-02 1.42
hsa-miR-27a 1.1E-03 1.24E-02 1.41
hsa-miR-138 5.0E-04 8.97E-03 1.38
hsa-miR-320 9.6E-04 1.24E-02 1.35
hsa-miR-30a 2.3E-03 2.17E-02 1.35
hsa-miR-193b 3.6E-03 2.77E-02 1.35
454_hsa_miR_2366 3.5E-03 2.77E-02 1.35
hsa-miR-339–5p 6.2E-03 3.98E-02 1.34
hsa-miR-455–5p 5.4E-03 3.59E-02 1.34
hsa-miR-3648 5.1E-03 3.51E-02 1.31
hsa-miR-92a 9.6E-03 5.92E-02 1.30
hsa-miR-152 3.7E-03 2.78E-02 0.75
hsa-miR-21 4.5E-03 3.25E-02 0.74
hsa_SNORD118 3.0E-05 1.34E-03 0.68
Footnote: Fold change values above 1 represent miRNAs with higher expression in isogenic non-metastatic vs. metastatic 
cell lines. Filters: Variance > 0.3, P < 0.01 (FDR = 0.06). hsa denotes human miRNAs. miRNAs in bold were further 
analyzed using qRT-PCR. The two microRNAs, 454_hsa_miR_2394 and 454_hsa_miR_2366, were identified by 454 deep 
sequencing [44] and have not been annotated in miRBase. hsa-miR-801 appears to be a fragment of U11 spliceosomal 
RNA, and is no longer annotated as a miRNA in miRBase.
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lines (Fig. 1A). Comparison of the miRNA profiles of the 
two metastatic cell lines, M-4A4 and LM3, showed no 
statistical differences.
An IPA analysis focusing on the 28 mature human 
miRNAs exhibiting significantly altered expression 
between the metastatic and non-metastatic cell line groups 
revealed a network consisting of 16 of the 28 miRNAs 
associated with functions in Cancer, Gastrointestinal 
Disease and Hepatic System Disease (Suppl Fig. 2). 
miR-155, the miRNA that exhibited the highest difference 
in expression between metastatic and non-metastatic 
cell line groups (>3 fold higher in the non-metastatic), 
appeared to be central in this network and was deemed a 
top candidate for further investigation.
Nine of the 28 miRNAs exhibiting altered expression 
in the array analysis were selected based on the miRNA 
fold change, identification in the literature of cancer 
involvement, and whether they were central in the IPA 
analysis (Table 1, Suppl Fig. 2). These 9 miRNAs were 
examined by qRT-PCR using the miRCURY LNA™ PCR 
system (Fig. 1B), and all nine exhibited the same miRNA 
expression pattern as seen in the miRNA microarray 
analysis, confirming the altered miRNA expression 
between the non-metastatic and metastatic groups.
High miR-155 expression in cancer cells inhibits  
the late steps of extravasation and/or 
colonization in the metastatic process
The CL16 cancer cell line, which is isogenic to 
NM-2C5, M-4A4 and LM3 cancer cells, but is more 
aggressive than M-4A4 and LM3 cells, exhibited the 
lowest miR-155 level of the three metastatic cell lines 
(Suppl Fig. 3). To examine the functional role of miR-155 
expression, miR-155 was overexpressed in CL16 (CL16-
miR-155) by lentiviral transduction, resulting in stable 
high expression of miR-155 (Suppl Fig. 3).
To study the effect of increased miR-155 expression 
on the process of metastatic seeding and secondary 
outgrowth, 7.8 × 105 CL16-miR-155 or CL16-Ctrl cells 
were injected intravenously (i.v.) into the tail vein of 
immunodeficient female CB-17 SCID mice (n = 6 in each 
group) and the tumor burden in the lungs was evaluated 
using bioluminescence. At endpoint, three weeks after 
injection, the metastatic burden was significantly lower in 
mice injected with CL16-miR-155 than those injected with 
CL16-Ctrl (p = 0.0087, Fig. 2A and 2B). Furthermore, 
measurements of the tumor burden over time showed that 
the CL16-miR-155 lung tumors grew slower compared to 
Figure 1: Heat map depicting unsupervised hierarchical clustering of metastatic and non-metastatic cell lines based on 
the differentially expressed miRNA measured by microarray and validation of miRNA alteration by qRT-PCR. A. Top: 
Blue: Non-metastatic cell line NM-2C5, Green: Low metastatic cell line M-4A4, Red: Intermediate metastatic cell line LM3. Red squares 
in the hierarchical clustering represent higher expression and green squares lower expression of a given miRNA. B. Relative fold change 
of nine miRNAs in the non-metastatic and metastatic cell line groups measured by microarray and qRT-PCR. Values above one correspond 
to higher expression in the non-metastatic vs. metastatic cell line groups. Standard deviation is measured between the two biological 
replicates, each performed in triplicates.
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the CL16-control tumors (Fig. 2C). The observed significant 
difference in endpoint tumor burden after i.v. injection, as 
well as the difference in lung tumor growth over time were 
confirmed in an independent experiment (n = 6 in each 
group) using the same setup (p = 0.041, Fig. 2D–2F). The 
difference in lung tumor burdens between the two groups 
of animals was also assessed by staining the excised lungs 
with an anti-human vimentin antibody (Fig. 2G). Subsequent 
quantification of the stained lung tumors confirmed the 
significant difference in lung tumor burden at endpoint 
between CL16-Control and CL16-miR-155 (Fig. 2H). 
Together, these results indicate that miR-155 expression in 
CL16 cells inhibits the later steps of the metastatic process, 
such as extravasation and/or colonization. The expression of 
miR-155 in the metastases was verified using qRT-PCR at 
the completion of the animal study (Suppl Fig. 4).
Evaluation of the underlying mechanism of the 
reduced tumor burden in lungs of high miR-155-
expressing cancer cells
To address the underlying mechanism of the 
reduced tumor burden in lungs observed after injection 
of CL16-miR-155 cells compared to injection of 
CL16-Ctrl cells, we stained the corresponding lung tumors 
to evaluate the apoptotic marker cleaved Caspase-3 and the 
proliferation marker Ki-67. Very few apoptotic cells were 
observed, and no differences between the two groups were 
seen (Fig. 3A). Larger Ki-67-positive cancer cell numbers 
were observed in lung sections of mice injected with CL16-
Ctrl cells than those injected with CL16-miR-155 cells, 
but as the lungs of the former group also demonstrated 
a larger overall tumor burden, the relative frequency of 
Figure 2: miR-155 decreases the tumor burden in lungs after i.v. injection. CL16-miR-155 or CL16-Ctrl cells (7.8 × 105) 
were injected into the tail vein of groups of female CB-17 SCID mice and tumor burden in lungs was monitored by bioluminescence 
imaging using an IVIS Spectrum instrument. A. IVIS images of the animals (photon radiance per area from the lung region) from the 
initial study (n = 6 in each group) at week 3, and B. comparison of the two groups using the Mann-Whitney statistical test (p = 0.0087). 
C. Increased tumor burden in lungs over time in the initial experiment measured by bioluminescence imaging starting one week after tumor 
cell injection. D, E. For the second animal study (n = 6 in each group), the IVIS scans (photon radiance per area from the lung region) at 
week 3 were also compared using the Mann-Whitney test (p = 0.041). F. Tumor growth in lungs in the second experiment measured by 
bioluminescence imaging over time starting one week after tumor cell injection. G. The difference in lung tumor burdens between the 
two groups of animals in the initial experiment was also visualized by staining the excised and FFPE lungs using an anti-human vimentin 
antibody. H. Quantitative evaluation of the differences in pulmonary foci/nodules (n = 6) in the initial experiment. Only tumors larger than 
100 μm were included. (*p < 0.05).
Oncotarget29229www.impactjournals.com/oncotarget
Ki-67-positive tumor cells in the two groups did not differ 
(Fig. 3B). We next examined CL16-miR-155 and CL16-Ctrl 
cells for their invasion capability using an in vitro invasion 
assay based on the Boyden chamber. CL16-miR-155 
cells showed significantly decreased invasion capability 
compared to CL16-Ctrl cells (student t-test, p = 0.028, 
Fig. 3C). To assure that the difference in invasion capability 
was not due to a difference in proliferation of CL16-
miR-155 and CL16-Ctrl cells, we concomitantly examined 
their proliferation in vitro using crystal violet and observed 
no difference (Fig. 3D).
Evaluation of the influence of miR-155 on the 
epithelial-like/mesenchymal-like phenotype
Since miR-155 has been reported to cause transition 
of cancer cells exhibiting an epithelial-like phenotype to a 
more mesenchymal-like phenotype, we evaluated possible 
changes in morphology and expression of E-cadherin 
(epithelial marker) and vimentin (mesenchymal marker) 
in our mesenchymal-like metastasis model. CL16-Ctrl 
and CL16-miR-155 cells grown in vitro and as xenograft 
tumors were analysed using contrast-phase microscopy 
and immunohistochemistry, respectively. Increased 
expression of miR-155 did not change the mesenchymal-
like morphology of CL16 cells (Fig. 4A), nor did it change 
the expression of vimentin or E-cadherin, as both CL16-Ctrl 
and CL16-miR-155 cells grown in vitro and in vivo showed 
high expression of vimentin and no E-cadherin expression 
(Fig. 4B). Thus, CL16 cancer cells, which already exhibit 
a mesenchymal-like phenotype, retain this phenotype 
regardless of increased miR-155 expression.
Identification of putative targets of miR-155
To identify proteins regulated directly or 
indirectly by miR-155, we compared the proteome 
of two CL16-miR-155-derived tumors with two 
CL16-Ctrl-derived tumors using mass spectrometry-based 
proteomics. The protein preparations of the tissue samples 
were separated in membrane, and soluble protein fractions 
and subjected to MS/MS-based proteomic analysis, 
which led to the identification of 3414 and 3059 proteins 
(4055 proteins total), respectively. Of these, 2260 and 
1873, respectively, were identified by at least two unique 
peptides (2639 proteins total). To increase the likelihood 
that the proteins were indeed regulated by miR-155, we 
focused on those identified by at least two unique peptides, 
and in which at least three of the four protein ratios of 
miR-155/Ctrl tumors were > 1.4 fold. Using these criteria, 
39 regulated proteins, 17 with lower expression and 22 
with higher expression in CL16-miR-155 vs. CL16-Ctrl 
xenograft tumors (Suppl Table 1), were identified in the 
membrane protein fraction, while 56 proteins, 33 with 
lower and 23 with higher expression in CL16-miR-155 
vs. CL16-Ctrl xenograft tumors (Suppl Table 2), were 
Figure 3: miR-155 overexpression inhibits invasion of metastatic CL16 cancer cells in vitro, but has no effect on 
proliferation or apoptosis. A. Immunohistochemical staining of lung tumors derived from i.v. injected CL16-miR-155 or CL16-Ctrl 
cells for the apoptotic marker cleaved Caspase-3 showed very few apoptotic cells and no difference between the two groups. B. Staining 
of the same lung tumors for the proliferation marker Ki-67 showed similar frequency of Ki-67-positive tumors cells in the two groups. 
C. CL16-miR-155 cells showed significantly decreased invasion capability compared to CL16-Ctrl (student t-test, p = 0.028) when evaluated 
in an in vitro invasion assay. A representative experiment out of 3 is shown. D. In the same experiment, no difference in proliferation in vitro 
was observed between the CL16-miR-155 and CL16-Ctrl cells.
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identified in the soluble protein fraction. Three proteins 
were identified as regulated in both the membrane and 
soluble samples [aldehyde dehydrogenase 1 (ALDH1A1), 
pirin (PIR) and acid ceramidase (ASAH1)], resulting in a 
total of 92 regulated proteins.
We next investigated the interactions of these 
92 regulated proteins in an IPA analysis and found two 
networks with high scores of 46 and 20, indicating 
the likelihood that the uploaded molecules in the 
network were linked by chance as calculated by the 
formula: –log(p-value). The main functions of the proteins 
in the first network, with a score of 46, were related to 
Lipid Metabolism, Small Molecule Biochemistry, 
and Cellular Movement (Fig. 5A). The network with 
the second highest score (n = 20) contained proteins 
with primary functions in Cell-To-Cell Signaling and 
Interaction, Cellular Growth and Proliferation, Cell 
Death and Survival (Fig. 5B). Interestingly, miR-155 
was included in this second network, indicating that the 
proteins we identified were indeed directly or indirectly 
regulated by miR-155. ALDH1A1 (network 1, Fig. 5A), 
and PIR (the most differentially expressed protein) were 
selected for further validation based on involvement in IPA 
network, regulation level and known cancer association. 
The tumor suppressor protein Programmed cell death 
protein 4 (PDCD4) was chosen because it is a validated 
miR-155 target. ALDH1A1, PIR and PDCD4 were all 
expressed at lower levels in CL16-miR-155-derived 
tumors than CL16-Ctrl-derived tumors.
To validate the altered expression of ALDH1A1, 
PIR and PDCD4, immunohistochemical stainings were 
performed on FFPE tissue blocks of the xenograft tumors, 
and average H-scores (Suppl Table 3) were calculated 
(n = 3–6). Good agreement with regard to staining 
intensity of tumors generated from the same cells was 
observed between the different mice. ALDH1A1, PIR 
and PDCD4 were all found to be less intensely stained 
in CL16-miR-155-derived tumors than CL16-Ctrl-
derived tumors (Fig. 6), confirming the proteomic results. 
Furthermore, immunocytochemical staining of NM-2C5 
and CL16 cells showed that ALDH1A1, in contrast to 
CL16, was not expressed in NM-2C5 (Fig. 6A), and 
PIR showed weaker expression in NM-2C5 than in 
CL16, correlating with high miR-155 expression in 
NM-2C5 (Fig. 6B). For the tumor suppressor PDCD4, 
strong staining was observed in both NM-2C5 and 
CL16 (Fig. 6C).
DISCUSSION
A high number of cancer cells dissociate from 
primary tumors and enter the circulation, but only a 
few have the ability to colonize and establish metastasis 
at distant sites. The metastatic process is complex and 
involves interactions between cancer cells and surrounding 
tissues in the new microenvironment, as well as cellular 
signaling within the cancer cells. The precise nature of 
these processes is poorly understood and is difficult to 
study in clinical samples. To gain insight into miRNA 
regulation in metastasis formation, we used a metastatic 
cell line model in which isogenic cell clones differ in their 
ability to extravasate, colonize, and form metastases at 
distant sites.
Global miRNA expression profiling identified miR-
155 as the most up-regulated miRNA in the non-metastatic 
NM-2C5 cell line compared to the metastatic M-4A4 and 
LM3 cell lines. Since NM-2C5 is capable of initiating 
the metastatic process in disseminating single cells to 
distant organs, but lacks the ability to expand and establish 
metastasis, we posited that miR-155 may inhibit essential 
steps in the extravasation/colonization process. This concept 
was supported by our in vivo experiments showing that 
overexpression of miR-155 in highly metastatic cancer cells 
decreased their ability to extravasate, colonize and form 
Figure 4: No difference in morphology, E-cadherin or vimentin expression was observed between CL16-miR-155 and 
CL16-Ctrl cells. A. Phase-contrast images showing that both CL16-miR-155 and CL16-Ctrl cells exhibit mesenchymal-like morphology 
in vitro. Objective 10x, numerical aperture NA 0.3. Scale bar 100 μm. B. Staining for E-cadherin and vimentin in metastasis from i.v. injection 
model and cells grown in vitro as determined by immunohistochemistry. Objective 100x, numerical aperture NA 1.25 Scale bar 20 μm.
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tumors in lungs when injected i.v, as well as decreased their 
invasion ability in vitro. A recent study by Gasparini and 
colleagues [14] showed that high miR-155 expression was 
correlated with better patient outcome in 160 triple-negative 
breast cancer patients, highlighting the clinical relevance of 
our findings in our cancer model. Other functions of miR-155 
in cancer have been reported, including a correlation 
between increased miR-155 levels and increased cancer 
invasion and migration [29]. Increased miR-155 levels have 
also been correlated with poor prognosis in different cancer 
types, including lung, liver, pancreas and breast cancer [8, 
9, 11, 30]. In a recent study, stable expression of miR-155 
in 4T1 breast cancer cells was found to inhibit spontaneous 
tumor dissemination from mammary fat pads to the lung 
by preventing epithelial-to-mesenchymal transition (EMT) 
[15]. Moreover, it was shown that miR-155 promoted tumor 
Figure 5: IPA network based on proteins exhibiting altered expression between CL16-miR-155- and CL16-Ctrl-
derived xenograft tumors. A. Network 1 with the highest score was related to Lipid Metabolism, Small Molecule Biochemistry, and 
Cellular Movement and B. Network 2 with the second highest score was related to Cell-To-Cell Signaling and Interaction, Cellular Growth 
and Proliferation, Cell Death and Survival. Red symbols indicate increased expression and green Red symbols indicate lower expression in 
CL16-miR-155- vs CL16-Ctrl-derived xenograft tumors.
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formation in the lung when cells were injected directly in 
the bloodstream. The discrepancy between their cell line 
models and ours likely relates to the fact that their 4T1 breast 
cancer cells exhibit epithelial-like characteristics, which are 
phenotypically influenced by miR-155, while our CL16 
cell line exhibits mesenchymal-like characteristics and, in 
contrast, was not phenotypically influenced by miR-155.
To better understand the function of miR-155, its 
possible targets were identified by proteome analysis 
in our in vivo metastasis model. Network analysis of 
the 92 proteins exhibiting altered expression between 
xenograft tumors derived from high miR-155 CL16 cells 
compared to those from CL16-Ctrl cells revealed that the 
altered proteins were associated with cellular functions 
such as movement, growth and survival, as well as cell- 
to-cell signaling and interaction. Lower protein expression 
of three of the identified putative miR-155 targets, 
ALDH1A1, PIR, and PDCD4, was further confirmed 
by immunohistochemical staining of xenograft tumors 
derived from high miR-155 CL16 cells compared to those 
from CL16-Ctrl cells, indicating inhibition of the three 
proteins by miR-155. The three proteins are known to be 
involved in metastasis formation and could therefore be 
effectors of the altered miR-155 in our model. ALDH1A1 
is a known cancer stem cell marker [31] associated with a 
poor prognosis in several cancer types [31–34]. PIR is an 
iron-binding protein likely functioning as a transcription 
cofactor, and protein expression of PIR in breast cancer 
tumors correlate with lymph node metastasis [35]. In 
melanocytic cells, knockdown of PIR has been shown to 
inhibit cell migration [36] and induce cellular senescence 
[37]. Further studies will determine whether these three 
proteins are direct or indirect miR-155 targets.
It should be noted that there is a continued debate 
as to whether the parental cell line of our cell line model, 
MDA-MB-435, originated from a breast cancer or a 
melanoma. MDA-MB-435 was originally derived from a 
pleural effusion of a patient with invasive ductal carcinoma 
[38], but the breast cancer origin was questioned when 
a microarray study showed a gene expression pattern 
primarily resembling melanoma cells [39]. However, other 
studies have shown that MDA-MB-435 expresses breast-
specific markers and can be induced to secrete milk lipids, 
a characteristic unique to breast cancer cell lines, thereby 
confirming it is a breast cancer cell line [40]. Montel 
and colleagues [41] later showed that surgically-excised 
primary human breast cancers, as well as other human 
breast cancer cell lines, also expressed melanoma-related 
Figure 6: Lower expression of putative miR-155 targets in xenograft tumors with high miR-155 
expression. Immunohistochemical staining of ALDH1A1 A. PIR B. and PDCD4 C. in tumors derived from CL16 cells transduced 
with either miR-155 or Ctrl vector. Expression of the three targets in non-metastatic NM-2C5 (high miR-155) and metastatic CL16 cells 
(low miR-155) grown in vitro was also evaluated. Objective 40x, Scale bar 50 μm.
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genes, demonstrating that this is a common phenomenon 
of breast carcinomas and confirming that MDA-MB-435 
is of breast cancer origin. Whether or not MDA-MB-435 
is a breast cancer cell line, the isogenic cell lines comprise 
a good representative model system for analyzing 
differences in cancer extravasation and colonization.
In summary, a panel of 28 miRNAs were 
identified that exhibited significantly altered expression 
in metastatic vs. non-metastatic cell lines and may 
be markers of the ability of cancer cells to colonize in 
distant organs. Increased expression of miR-155 in 
metastatic cancer cells decreased their metastatic seeding 
and secondary tumor outgrowth in vivo when injected 
i.v. into immunodeficient mice, further supporting a role 
of miR-155 in later steps of the metastatic process by 
inhibition of cancer cell extravasation and/or colonization 
in distant organs. In addition, our results and those of 
others indicate that the effects of miR-155 on metastasis 
are dependent on the epithelia-like/mesenchymal-like 
phenotype of the cancer cells.
MATERIALS AND METHODS
Cell lines and culture conditions
The human cancer cell lines NM-2C5 GFP 
(NM-2C5), M-4A4 GFP (M-4A4), M-4A4-LM3–2 GFP 
(LM3), (American Type Culture Collection (ATCC), 
Manassas, VA, USA) and M-4A4-LM3–4 CL-16 
GFP LUC2 (CL16) [42] were cultured in Dulbecco's 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, 
MO, USA) supplemented with 10% fetal bovine serum 
(FBS) (Sigma-Aldrich) and 1% Penicillin/Streptomycin 
(Final concentration: 100 Units/ml Penicillin, 100 μg/ml 
Streptomycin) (Sigma-Aldrich). The isogenic cell lines 
NM-2C5 and M-4A4 were selected from a large panel of 
tumor subclones derived by serial dilution of the metastatic 
cancer cell line MDA-MB-435 that was systematically 
tested for metastatic behavior in immunodeficient mice 
[16]. LM3 was established by expanding isolated cells 
from lung metastases in mice inoculated with M-4A4 cells 
[18]. Similarly, cells were isolated from mice inoculated 
with LM3 and expanded to the M-4A4-LM3–4 CL-16 
GFP (CL16) cell line [18–20]. When inoculated into 
immunodeficient mice, LM3 was more metastatic than 
M-4A4 (100% vs. 62%, respectively), establishing 2 cm 
tumors at 79 vs. 113 days, and 14 vs. 4 metastatic deposits 
per lung [18]. CL16 is even more metastatic than M-4A4 
and LM3 [19, 20].
Global miRNA array analysis
Total RNA was isolated using TRIzol (Invitrogen, 
Carlsbad, California, USA) from the NM-2C5, M-4A4 
and LM3 cell lines according to the manufacturer’s 
instructions. Global miRNA expression analysis was 
performed using the miRCURY LNA (Locked Nucleic 
Acid) microRNA Arrays (Exiqon, A/S, Vedbaek, 
Denmark) version 10.0, which, in addition to 1200 
probes targeting all human, mouse and rat miRNA 
sequences annotated in miRBase 10.0, also include 66 
probes that target proprietary microRNAs identified by 
deep sequencing [43, 44]. Two independent purifications 
were made from each cell line and miRNA expression 
was measured for each on two different arrays relative 
to one of the other cell lines using dual color array. The 
arrays were scanned in an Agilent G2565BA Microarray 
Scanner System (Agilent Technologies, Santa Clara, CA, 
USA), and these fluorescence images were analyzed 
using ImaGene™ software (BioDiscovery, CA, USA). 
A grid was placed on the array and the image signal 
and background intensities were measured for each spot 
in both dye channels. Normalization and background 
corrections were performed in the statistical programming 
language R with the Bioconductor [45] software package 
LIMMA (Linear Models for Microarray Data) [46]. Poor 
quality spots were removed and spots were background-
corrected using the Normexp method (with an offset of 
50). All fluorescence intensities were log2-transformed, 
and normalization was performed using LOESS (Locally 
weighted scatterplot smoothing) [47]. Data was visualized 
in heat-maps with two-way unsupervised hierarchical 
clustering using Qlucore Omics Explorer v.2.2 (Qlucore 
AB, Lund, Sweden).
Microarray qRT-PCR verification
Verification of the miRNA microarray analysis 
was conducted using the miRCURY LNA™ microRNA 
PCR system (Exiqon) according to manufacturer’s 
instructions. For each miRNA assay, three separate 
cDNA syntheses were performed for each of two 
biological replicates followed by a qPCR reaction. 
Quantitative Reverse Transcription PCR (qRT-PCR) 
was performed using an Applied Biosystems 7500 
PCR Instrument (Applied Biosystems, Foster City, 
CA, USA). To verify specificity and identity of the 
miRNAs, a melting/dissociation curve was conducted 
for each miRNA after the qRT-PCR run. The baselines 
of the qRT-PCR runs were automatically set by the PCR 
instrument, while the threshold for fluorescence was 
manually set in the exponential phase. The inclusion 
criteria of Ct values were as follows: Ct value between 
replicates below 0.5, and amplification of at least two 
replicates. Furthermore, the quality of the qRT-PCR 
run was analyzed by examination of the amplification 
plot and the melting temperature curve. The stability 
of 5 candidate reference genes was tested using qBase 
v.1.3.4 [48] and geNorm [49] to identify the most stable 
reference genes in the three cell lines. The qRT-PCR data 
was normalized and analyzed using the ∆∆Ct method 
[50]. ∆Ct values were normalized using the geometric 
mean of the three most stable endogenous reference 
genes, U6 snRNA, 5S rRNA and hsa-miR-191.
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Immunocytochemistry and 
immunohistochemistry
Tissue and cell lines were formalin-fixed and 
paraffin-embedded (FFPE), and sections (4 μm) were 
cut from the FFPE blocks mounted on slides, dried, 
deparaffinized and hydrated. Endogenous peroxidase 
activity was blocked for 10 min with 1.5% hydrogen 
peroxide in TBS (Tris buffered saline) buffer, pH 7.4. 
Epitope retrieval for E-cadherin staining was performed 
by incubating slides in CC1 buffer (Ventana, Roche, 
Tucson, USA) for 32 min at 100°C. Slides were then 
incubated with mouse monoclonal anti-E-cadherin 
antibody (E-cadherin (36), 790–4497, Ventana, Roche) 
for 12 min at 36°C. Primary antibody detection was 
performed with OptiView (Ventana, Roche) on a Dako 
AutoStainerPlus (Dako). For the rest of the antibodies, 
a panel of epitope retrieval protocols and antibody 
dilutions were initially evaluated, and incubation 
for 15 min in TE (Tris/EDTA, pH 9) buffer (Dako) 
was found to be optimal for mouse monoclonal anti-
vimentin antibody (VimentinV9, M0725, Dako, 1:1000). 
Heat-induced epitope retrieval by microwave boiling 
for 15 min in T-EG buffer (Tris/EGTA, pH 9) was 
found to be optimal for the rabbit polyclonal primary 
antibodies ALDH1A1 (31160002, Novus Biologicals, 
CO, USA, diluted 1:4000), PIR (HPA000697, Sigma-
Aldrich, diluted 1:50), PDCD4 (HPA027214, Sigma-
Aldrich, diluted 1:50), cleaved Caspase-3 (ASP175, 
Cell signaling tech, diluted 1:400) and Ki-67 (Dako 
M7240, diluted 1:200). Antibodies were diluted in 
antibody diluent S2022 (Dako, Glostrup, Denmark) 
and incubated on slides for 1 hour at room temperature. 
Slides were subsequently washed with TNT buffer 
(Tris/NaCl/Tween20, pH 7.5) and immunostained 
using EnVisionTM+ system-HRP labeled Polymer Anti 
Rabbit or Anti Mouse detection system (Dako) on a 
DakoAutostainerPlus (Dako). 3,3-Diaminobenzidine 
(DAB, Dako) was used as the substrate chromogen 
system for all antibodies and nuclear counterstaining 
was performed for 2 min in Mayer’s hematoxylin. 
ALDH1A1, PIR and PDCD4 were evaluated using the 
histo-score (H-score), which combines the intensity of 
the staining with the number of positive cells and is 
calculated by adding the percentage of cells with weak 
intensity staining with 2 times the percentage of cells 
with moderate intensity staining, and then further adding 
3 times the percentage of cells with strong intensity 
staining, resulting in a score between 0 and 300.
Generation of CL16-miR-155 and  
CL16-control cells
LUC2-transduced CL16 cells [42] were harvested, 
washed in PBS and diluted in complete medium 
containing 5 μg/ml of polybrene (Sigma-Aldrich). Fifty 
thousand cells were transferred to a 24-well plate and 
transduced with miR-155 or control lentiviral particles 
(Applied Biological Materials Inc., Richmond, Canada) at 
a multiplicity of infection (MOI) of 2.5 generating stably 
miR-155 expressing CL16 cells (CL16-miR-155) and 
CL16 control cells (CL16-Ctrl).
In vivo studies
Sub-confluent cells in culture were washed in 
PBS and harvested by scraping, resuspended in PBS at 
a concentration of 3.9 × 106/ml, and 0.2 ml injected into 
the tail vein of 8-week-old female CB-17 SCID mice 
(Taconic). All animal experiments were approved by The 
Experimental Animal Committee, The Danish Ministry 
of Justice and performed at the animal core facility at 
University of Southern Denmark. The mice were housed 
under specific pathogen-free conditions with ad libitum 
food and drinking water. The mice were euthanized if 
they showed any adverse signs or symptoms of disease, 
including weight loss, paralysis or general discomfort. 
Relative quantification of tumor burden in lungs upon 
i.v. administration of cells was performed weekly using 
bioluminescent imaging (IVIS-spectrum, Perkin Elmer, 
Massachusetts, USA). Mice were injected with 150 mg 
D-luciferin/kg body weight and then anaesthetized with 
isoflurane gas. Images were acquired starting 10 min 
after luciferin injection. Regions of interest (ROI) were 
drawn encircling the thorax region to quantify metastases. 
The photon emission transmitted from the ROIs was 
quantified in photons/s/cm2/sr using Caliper Life Science 
Living image (version 4.2). The statistical significance 
of bioluminescence measurements of tumor burden in 
different groups was calculated using the Mann-Whitney 
statistical test.
Verification of miR-155 overexpression
Verification of miR-155 expression in CL16 
LUC2 cells transduced with virus packaged with vector 
encoding miR-155 in vitro and in vivo was conducted 
using the miRCURY LNA™ Universal RT microRNA 
PCR (Exiqon) according to manufacturer’s instructions. 
qRT-PCR reactions were performed on a StepOnePlus™ 
Real-Time PCR Instrument (Applied Biosystems).
Cell invasion assay
The cell invasion assay was performed using 
the QCM ECMatrix 24-well kit (Chemicon, ECM550, 
USA) according to the manufacturer’s instructions. Each 
lower chamber contained 500 ul DMEM with 10%FBS 
as the chemoattractant. CL16-mir155 og CL16-ctrl cells 
(2 × 105) in DMEM were placed into the upper chamber 
and then incubated for 48 h at 37°C in a humidified 
atmosphere containing 5% CO2. After incubation, non-
migrating cells in the top chambers were completely 
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removed by pipetting out the remaining cell suspension, 
and placing the invasion chamber insert into a clean 
well containing 225 μl of prewarmed Cell Detachment 
Solution for 30 minutes at 37°C. To the lower chambers 
75 μl Lysis Buffer/Dye Solution was added to each well 
containing 225 μl cell detachment solution with the cells 
that invaded through the ECMatrix-coated membrane 
and incubation for 15 minutes at room temperature. 
180 μl of the mixture was transferred of to a 96-well 
plate suitable for fluorescence measurement and analyzed 
with a fluorescence plate reader using 485/535 nm filter 
set. All experiments were performed in triplicate. Three 
independent experimental were performed with similar 
results.
Target identification by proteomic analysis: 
Separation of soluble and membrane proteins 
from tumor tissue
CL16-miR-155- and CL16-Ctrl-derived xenograft 
tumors generated in the mammary fat pads were placed in 
homogenization tubes (Nalgene, Thermo Scientific, CA, 
USA) with 1 ml 0.1M Na2CO3, pH 11 and 600 mg 0.5 mm 
glass beads (Bertin Technologies, Martigny, France) and 
homogenized in a Precellys24 (Bertin Technologies) 
twice at 5000 rpm for 30 sec with incubation on ice for 
2 min in between. The lysate was transferred to 4 ml 
ultracentrifugation tubes and 1 ml 0.1 M Na2CO3 was 
added to the remaining tumor tissue. This homogenization 
step was performed three times (6 × 5000 rpm). The lysate 
was incubated for 1 h at 4°C and then ultracentrifuged 
at 100,000 × g for 30 min at 20°C. The supernatant 
(containing the soluble proteins) was transferred to a 
second tube while approximately 300 μl 8 M Urea, 0.1 M 
Tris/Hcl, pH 8.5 (UA) was added to the pellet (containing 
the membrane proteins). The pellet was dissolved using 
a pestle and shaken overnight at room temperature. 
Five volumes of acetone were added for 1 h at −80°C to 
precipitate soluble proteins. The solution was centrifuged 
at 2300 × g for 30 min and the supernatant was removed. 
The pellet was washed twice with 1 ml ice-cold acetone, 
centrifuged at 2300 × g for 10 min and air-dried for 10 min 
prior to being dissolved in 500 μl UA.
Protein desalting, digestion and iTRAQ labeling
Protein concentrations were measured in triplicate 
using a colorimetric assay (Bio-Rad, Hercules, CA, 
USA) according to the manufacturer’s instructions with 
a BSA standard. Two hundred μg of each sample was 
purified using a modified version of Filter Aided Sample 
Preparation [51]. In brief, the samples were placed on 
Amicon Ultra-0.5 mL Centrifugal Filters, Ultracel-
10K filters (Merck Milipore, Tullagreen, Ireland), UA 
was added to a final amount of 200 μl in the filter and 
centrifuged at 14,000 × g for 15 min. This was repeated 
twice followed by 15 min incubation with UA and 
centrifugation at 14,000 × g for 15 min (flow-through 
discarded). The proteins were reduced with 200 μl UA 
containing 10 mM DTT, placed in a closed chamber at 
56°C for 30 min and centrifuged at 14,000 × g for 15 min. 
To alkylate the proteins, 100 μl 0.05 M iodoacetamide was 
added, mixed at 600 rpm for 1 min and incubated at room 
temperature in the dark for 20 min. The filters were then 
centrifuged three times at 14,000 × g for 15 min, washed 
twice with 100 μl 50 mM Tetraethylammonium bromide 
(TEAB, Sigma-Aldrich) and centrifuged at 14,000 × g 
for 10 min (flowthrough discarded). The proteins were 
then digested with Sequencing Grade Modified Trypsin 
(Promega, Madison, WI, USA) and mixed at 600 rpm 
for 1 min. Samples were incubated for 17 hours in a 
wet chamber at 37°C. The filters were placed in new 
collection tubes and centrifuged 14,000 × g for 10 min. 
Forty μl 50 mM TEAB was added to each filter and 
centrifuged 14,000 × g for 10 min. Flow-through was 
acidified with formic acid (FLUKA, Sigma-Aldrich) 
to a total concentration of 5%. In addition to the Filter 
Aided Sample Preparation, 500 μg of protein was 
directly reduced with 10 mM DTT for 30 min at 56°C 
and alkylated with 20 mM iodoactemide for 30 min 
at room temperature in the dark. These samples were 
digested with 10 μg Lys-C (Wako, Richmond, VA, 
USA) for 3 hours at room temperature, diluted 8 times 
with 50 mM TEAB and further digested with 10 μg 
Sequencing Grade Modified Trypsin (Promega). Samples 
from the two different digestion methods were processed 
in the same way. The digested peptides were desalted and 
concentrated on Empore C8 Extraction Disks (Empore™, 
Sulpeco, PA, USA), with Reverse Phase Resin Oligo R3 
(Applied Biosystems) and Reverse Phase R2 (Applied 
Biosystems) packed in 20 μl GELoader tips (Eppendorf, 
Hamburg, Germany) using a modified version of that 
reported by Rappsilber and colleagues [52, 53]. Peptide 
concentrations were measured in triplicate using the 
colorimetric assay from Bio-Rad using a modified version 
of the manufacturer’s instructions with a BSA standard 
in H2O. Twenty-two μg of each protein sample were 
iTRAQ−-labeled (iTRAQ Reagent 4Plex, AB SCIEX, 
MA, USA) according to manufacturer’s instructions. The 
four soluble protein samples (iTRAQ label: 114, 115, 116 
and 117) were combined in one tube, as were the four 
membrane protein samples. These two iTRAQ-labeled 
samples were then desalted and concentrated as described 
above.
HILIC fractionation and nano-LC-MS/MS 
analysis
The iTRAQ-labeled peptides were fractionated 
by hydrophobic interaction liquid interaction 
chromatography (HILIC) using the fraction collection 
option on the Dionex UltiMate 3000 nano/capillary 
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High-performance liquid chromatography (HPLC) 
system (Thermo Scientific). Briefly, peptide samples 
were loaded onto a customized HILIC column packed 
with TSKgel Amide-80 column material (Tosoh 
Bioscience LLC, PA, US) (3 μm bead size, 15 cm 
length, 300 μm inner diameter). The resulting fractions 
(n = 23) were analyzed in duplicate by nanoscale liquid 
chromatography coupled to tandem mass spectrometry 
(nano-LC MS/MS) using a Dionex UltiMate 3000 
nano HPLC coupled to an Orbitrap Q-Exactive mass 
spectrometer (Thermo Scientific). Samples were 
separated using nano HPLC. Briefly, samples (5 μl) were 
loaded onto a customized fused capillary pre-column 
(2 cm length, 360 μm outer diameter, 75 μm inner 
diameter) with a flow of 5 μl per min for 7 minutes. 
Trapped peptides were separated on a customized 
fused capillary column (20 cm length, 360 μm outer 
diameter, 75 μm inner diameter) packed with ReproSil 
Pur C18 3-μm resin (Dr. Maish, Ammerbuch-Entringen, 
Germany) with a flow of 250 nl per min using a linear 
gradient from 95% solution A (0.1% formic acid) to 35% 
B (99.9% Acetonitrile in 0.1% formic acid) over 30 or 
86 min, followed by 10 min at 90% B and 14 min at 
98% A. Mass spectra were acquired in positive ion mode 
applying automatic data-dependent switch between one 
Orbitrap survey MS scan in the mass range of 400 to 
1500 m/z followed by HCD (Higher-energy collisional 
dissociation) fragmentation and Orbitrap detection of the 
ten most intense ions observed in the MS scan. Target 
value in the Orbitrap for MS scan was 1,000,000 ions at 
a resolution of 70,000 at m/z 200. Peptide fragmentation 
in the HCD cell was performed at normalized collision 
energy of 30 eV. Ion selection threshold was set to 
17,000 or 33,000 counts. Selected sequenced ions were 
dynamically excluded for 45 sec.
Proteomic data analysis
A combined MASCOT-SEQUEST was performed 
where peak lists (mgf files) were processed using the 
Proteome Discoverer 1.4, version 1.4.0.288 (Thermo 
Scientific). Search parameters were set to MS accuracy 
10 ppm, MS/MS accuracy 0.1 Da for HCD data, with 
two missed cleavages allowed, fixed modification of 
cysteine blocked with carbamidomethyl, and lysine 
and N-terminal iTRAQ, and variable modifications; 
methionine oxidation, lysine- and deamidated 
asparagines. Tandem mass spectra were searched 
against the Uniprot-Swissprot database, downloaded 
October 2012. False discovery rates were obtained 
using Percolator selecting identification with a q-value 
≤ than 0.01. iTRAQ quantification was performed 
using Proteome Discoverer (Thermo Scientific) with 
reporter ion area integration within a 20 ppm window. 
Ratios were normalized against the median peptide 
ratio. The four-plex data was analyzed as ratios for each 
combination of the CL16-miR-155- samples (iTRAQ 
label 114 and 115) to the CL16-Ctrl samples (iTRAQ 
label 116 and 117), in all four ratios (114/116,114/117
,115/116,115/117). For both the membrane and soluble 
protein samples, the data from Proteome Discoverer 1.4 
was extracted and selected based on proteins identified 
by ≥ 2 unique peptides, with at least three of the four 
ratios above a fold-change of 1.4 and the fourth ratio at a 
minimum being in the same direction as the other three.
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis (IPA) (Ingenuity® 
Systems, http://www.ingenuity.com, release date 
2013–12-06) was used to evaluate whether miRNAs 
differentially expressed between the metastatic and non-
metastatic cell lines were part of functionally related 
integrated and interconnected biological networks. 
Differentially expressed miRNA identifiers were 
uploaded into IPA to map and generate putative networks 
based on curated knowledge database of pathway 
interactions extracted from the literature. The gene 
networks were generated using both direct and indirect 
relationships and only molecules and/or relationships 
experimentally observed or highly predicted were 
included in the analysis. The networks were ranked by 
probability scores assessing miRNA inclusion in the 
network by chance. miRNAs that appeared to be central 
in relevant networks were regarded as top candidates 
for further investigation. An IPA analysis was also 
conducted for the 92 proteins regulated between the 
CL16-miR-155 and CL16-Ctrl xenograft tumors, 
including both direct and indirect relationships. Only 
molecules and/or relationships experimentally observed 
or highly predicted were included in the analysis.
Statistical analysis
miRNAs differentially expressed between the 
two metastatic cell lines (M-4A4 and LM3) compared 
to the non-metastatic cell line (NM-2C5) in the 
miRNA array analysis were identified by a Student’s 
t-test with Benjamini-Hochberg False Discovery Rate 
[54] correction (Var > 0.3, P < 0.01 (FDR = 0.06)). 
Data were visualized by heat-maps with two-way 
unsupervised hierarchical clustering using Qlucore 
Omics Explorer v.2.2 (Qlucore AB, Lund, Sweden). 
Statistical significance of qRT-PCR data was calculated 
using a Student’s t-test (p < 0.05). The p values > 0.05 
were considered non-significant.
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